Compare SCSC & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCSC | IOVA |
|---|---|---|
| Founded | 1992 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 909.7M | 881.3M |
| IPO Year | 1994 | N/A |
| Metric | SCSC | IOVA |
|---|---|---|
| Price | $40.38 | $2.62 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 12 |
| Target Price | ★ $43.00 | $10.45 |
| AVG Volume (30 Days) | 158.6K | ★ 11.8M |
| Earning Date | 02-05-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1.79 | N/A |
| EPS | ★ 3.20 | N/A |
| Revenue | ★ $3,004,880,000.00 | $250,425,000.00 |
| Revenue This Year | $5.40 | $60.71 |
| Revenue Next Year | $5.34 | $59.52 |
| P/E Ratio | $12.73 | ★ N/A |
| Revenue Growth | N/A | ★ 175.62 |
| 52 Week Low | $28.75 | $1.64 |
| 52 Week High | $51.66 | $6.50 |
| Indicator | SCSC | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 49.39 | 55.64 |
| Support Level | $39.34 | $2.21 |
| Resistance Level | $41.78 | $2.72 |
| Average True Range (ATR) | 1.08 | 0.19 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 53.46 | 73.73 |
ScanSource Inc provides value-added services for technology manufacturers and sells to resellers in specialty technology markets. The firm's operations are organized in two segments: Specialty Technology Solutions and Intelisys & Advisory Segment. It generates maximum revenue from the Specialty Technology Solutions segment. The Specialty Technology Solutions segment includes the company's business in mobility and barcode, POS, payments, security and networking technologies. Geographically, it derives a majority of revenue from the United States and Canada, and also has its presence in Brazil, and other countries.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.